Enodia Therapeutics is a French biotech company building a proprietary small-molecule platform that selectively modulates the SEC61 translocon, a central control point of the protein secretion pathway.
By intervening at the point of synthesis, Enodia redirects disease-driving secreted and transmembrane proteins toward early degradation, before they mature or exert pathological effects, while preserving normal cellular function.
Leveraging a deep, well-characterized chemical space of SEC61 inhibitors, together with proteomics and machine-learning–guided drug design, Enodia enables highly selective, upstream intervention across multiple indications, starting with inflammatory and autoimmune diseases.

Enodia Therapeutics

Org chart

Teams

Offices

Enodia Therapeutics

Org chart

Teams

Offices

Related companies